ArticleBlood cancer journal2026

Real-world treatment patterns and outcomes of brentuximab vedotin-based therapy in CD30-positive lymphomas in China: the prospective BRAVE study.

Ming-Ci Cai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.